The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.
 
Ticiana Leal
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Daiichi-Sankyo; Eisai; EMD Serono; EMD Serono; Genentech; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Merck; Mirati Therapeutics; Novocure; Novocure; Novocure; Regeneron; Roche; Takeda; Takeda
Research Funding - Pfizer (Inst)
 
Rupesh Kotecha
Honoraria - Accuray; BrainLAB; Castle Biosciences; Elekta; Elsevier; Kazia Therapeutics; Peerview
Consulting or Advisory Role - Novocure; ViewRay
Speakers' Bureau - GT Medical Technologies (I); Novocure
Research Funding - AstraZeneca (Inst); Blue Earth Diagnostics (Inst); BrainLAB (Inst); Cantex Pharmaceuticals, Inc. (Inst); Exelixis (Inst); GT Medical Technologies (Inst); Medtronic (Inst); Novocure (Inst); ViewRay (Inst)
Travel, Accommodations, Expenses - Elekta; Novocure; Peerview; ViewRay
 
Rodryg Ramlau
Consulting or Advisory Role - AstraZeneca; BMS; Boehringer Ingelheim; Merck; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; BMS; Boehringer Ingelheim; Roche
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Speakers' Bureau - AstraZeneca; BeiGene; HenRui; Innovent Biologics; Roche China
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)
 
Janusz Milanowski
No Relationships to Disclose
 
Manuel Cobo-Dols
No Relationships to Disclose
 
Jaromir Roubec
No Relationships to Disclose
 
Lubos B. Petruzelka
No Relationships to Disclose
 
Libor Havel
No Relationships to Disclose
 
Sujith R. Kalmadi
Speakers' Bureau - AstraZeneca; Bayer; G1 Therapeutics; Genentech; Pfizer
 
Jeffrey P. Ward
Employment - Millipore (I); Pfizer (I)
Consulting or Advisory Role - Guidepoint Inc; Novocure; Takeda
Research Funding - AstraZeneca (Inst); Genmab (Inst); Harpoon therapeutics (Inst); Instil Bio (Inst); Novocure (Inst); Pfizer (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Halozyme
 
Zoran Andric
No Relationships to Disclose
 
Thierry Berghmans
No Relationships to Disclose
 
David E Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - BeiGene; Catalyst Pharmaceuticals; Daichi Sankyo; Janssen Oncology; Mirati Therapeutics; Regeneron; Sanofi
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Karyopharm Therapeutics (Inst); Novocure (Inst)
Patents, Royalties, Other Intellectual Property - Co-founder, Chief Scientific Officer, OncoSeer Diagnostics, LLC; Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.; UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 4153 - US Patent Application 63/386,387 IMMUNOTHERAPY TOXICITY – CELL PHENOTYPES; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb
 
Goetz Kloecker
Stock and Other Ownership Interests - Index funds for IRA
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; Merck; Novartis; Regeneron
Consulting or Advisory Role - Primum
Patents, Royalties, Other Intellectual Property - McGraw-Hill Education
Travel, Accommodations, Expenses - Kentucky Society Of Clinical Oncology
 
Rajiv Prasanna Panikkar
Travel, Accommodations, Expenses - Execute Council Member NCODA
 
Joachim Aerts
Leadership - IASLC
Stock and Other Ownership Interests - Amphera
Honoraria - AstraZeneca; Lilly O.; MSD
Consulting or Advisory Role - Amphera; AstraZeneca; Bristol-Myers Squibb; MSD; Takeda
Patents, Royalties, Other Intellectual Property - Biomarker for immunotherapy; Tumor cell lysate
 
Angelo Delmonte
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Novartis; Sanofi; Takeda
Travel, Accommodations, Expenses - MSD; Roche
 
Miklos Pless
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers-Squibb; Eisai Europe; Merck Serono; MSD Oncology; Novartis; Pfizer/EMD Serono; Roche; Takeda
Speakers' Bureau - AstraZeneca; Janssen; MSD; Nestle health science
Expert Testimony - Novartis; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers-Squibb; Daiichi Sankyo Europe GmbH; Roche; Takeda; Vifor Pharma
 
Corey J. Langer
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Heat Biologics; Merck; Mirati Therapeutics; Novocure; Pfizer; Regeneron; Sanofi; Takeda
Research Funding - AstraZeneca; Boehringer Ingelheim; Inovio Pharmaceuticals; Lilly O.; Merck; OncoCyte; Takeda; Trizell
Other Relationship - Novartis